Drug intelligence / Profile preview

HPN229

Development stage: Unknown
Modality: Peptides

Overview

**HPN229** is a peptide epitope derived from human hepsin (HPN), a type II transmembrane serine protease overexpressed in prostate cancer cells. It functions as an HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope, capable of stimulating IFN-γ-producing CD8+ T cells in vitro, suggesting potential utility in cancer immunotherapy targeting prostate tumors. Identified in research on tumor-associated antigens, HPN229 enhances T-cell responses compared to negative control peptides when evaluated alongside other hepsin-derived epitopes like Hpn268 and Hpn199[6][12].

Targets

HPN (Hepsin)

Beyond the preview

Go deeper on HPN229.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPN229.

Explore the full profile